PRESS RELEASE
Jerusalem startup Sweetch nets $3.5M investment for diabetes prediction technology
With tech giant Philips and hybrid venture capitalist group OurCrowd leading the way, another Jerusalem health startup is celebrating a multimillion dollar Series A right now. Sweetch announced on Thursday that it had raised $3.5 million for its diabetes prediction platform. The round also included Pontifax LP and Lionbird LP.
Sweetch Health Raises $3.5M From OurCrowd And Philips
Israeli digital health startup Sweetch Health, which has developed a “digital vaccine” for diabetes, has raised $3.5 million in a Series A round led by OurCrowd, a leading equity crowdfunding platform, and Philips, a leading health technology company. Participation from prior investors also included Pontifax L.P. and Lionbird L.P. Sweetch Health has developed a revolutionary […]
Israeli digital health startup to predict diabetes risk raises $3.5M
In the latest startup to join the war against diabetes, Sweetch has raised $3.5 million in a Series A round led by equity crowdfunding platform OurCrowd and Philips, according to the website, NoCamels. The company is focused not on people who have been diagnosed with the chronic condition, but for those who are at risk […]
Daily Funding Roundup
Jerusalem health startup Sweetch raised $3.5 million for its diabetes prediction platform. OurCrowd led the round, also participated Pontifax LP and Lionbird LP. Sweetch is led by CEO Dana Chanan, CTO Dan Lichtenfeld and Chief Medical Officer Yossi Bahagon, MD. They aim to use the funds to complete a pilot program and begin clinical trials.
OurCrowd & Philips Join to Raise $3.5 Million for Sweetch MedTech Startup
Sweetch Health, an Israeli medtech startup that has developed a “digital vaccine” for diabetes, has received series A funding in the amount of $3.5 million. The funding round was led by global conglomerate Philips and leading equity crowdfunding platform OurCrowd. The funding also saw participation from earlier investors including Lionbird and Pontifax.